酪氨酸激酶靶向癌症治疗的进展

Future Prescriber Pub Date : 2008-07-07 DOI:10.1002/fps.14

Dr Mike Leahy

{"title":"酪氨酸激酶靶向癌症治疗的进展","authors":"Dr Mike Leahy","doi":"10.1002/fps.14","DOIUrl":null,"url":null,"abstract":"<p>It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 2","pages":"20-23"},"PeriodicalIF":0.0000,"publicationDate":"2008-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.14","citationCount":"0","resultStr":"{\"title\":\"The evolution of tyrosine-kinase-targeted cancer therapies\",\"authors\":\"Dr Mike Leahy\",\"doi\":\"10.1002/fps.14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"7 2\",\"pages\":\"20-23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.14\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The evolution of tyrosine-kinase-targeted cancer therapies

It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量